Our goal is that all patients, whoever they are and wherever they live, can have access to effective treatment to treat and overcome the lesions caused by HPV. For this reason, since the launch of the Papilocare® family in 2016, we have strengthened and consolidated our international presence in different parts of the planet. And we will continue to do so to go even further.

Procare Health has signed distribution agreements with local pharmaceutical companies in more than 65 countries around the world. Currently, 45 countries are already commercializing our products, the remaining countries are undergoing their local regulatory processes at different stages to register the products according to their local requirements.